Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives $10.33 Average Price Target from Analysts

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have been assigned a consensus rating of “Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $10.3333.

A number of equities analysts have weighed in on NAGE shares. Freedom Capital upgraded Niagen Bioscience to a “strong-buy” rating in a research note on Monday, July 6th. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. HC Wainwright reissued a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, July 1st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Friday, July 17th.

Niagen Bioscience Stock Performance

Niagen Bioscience stock opened at $3.11 on Friday. The stock has a market cap of $247.68 million, a P/E ratio of 17.28 and a beta of 2.09. Niagen Bioscience has a fifty-two week low of $2.87 and a fifty-two week high of $10.52. The firm’s fifty day moving average price is $3.26 and its 200-day moving average price is $3.96.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a return on equity of 17.95% and a net margin of 12.39%. Sell-side analysts predict that Niagen Bioscience will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new position in Niagen Bioscience in the 3rd quarter worth $3,678,000. Vanguard Group Inc. bought a new stake in Niagen Bioscience in the third quarter worth $37,522,000. Ameritas Investment Partners Inc. purchased a new stake in Niagen Bioscience during the third quarter valued at about $45,000. Intech Investment Management LLC purchased a new stake in Niagen Bioscience during the third quarter valued at about $202,000. Finally, Quantbot Technologies LP bought a new position in shares of Niagen Bioscience during the third quarter valued at about $48,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.